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Abstract:
Background: The interaction between the dopaminergic and somatostatinergic systems and their role in mood regulation have been
well-documented. Therefore, we decided to investigate the effect of antidepressant drugs on the heterodimerization of the dopamine
D2 and somatostatin Sst5 receptors.
Methods: The human receptor proteins were tagged with fluorescent proteins, expressed in the HEK 293 cells and incubated with
antidepressant drugs: desipramine and citalopram. To determine the FRET efficiency, the fluorescence resonance energy transfer
(FRET) and photobleaching confocal microscopy techniques were used.
Results: We found that the efficiency of FRET is markedly increased in cells coexpressing the somatostatin Sst5 and dopamine D2
receptors after 48 h of incubation with desipramine and citalopram.
Conclusions: In the present study we provide physical evidence, based on FRET analysis, that antidepressants increase Sst5 and D2
receptors heterodimerization. The effect is specific because desipramine in the incubation medium uncouples other pairs of recep-
tors, such as the dopamine D1-D2 receptors.
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Abbreviations: CFP – cyan fluorescent protein, CIT – citalo-
pram, D2 – dopamine type 2 receptor, DMI – desipramine,
FRET – Förster (Fluorescence) Resonance Energy Transfer,
GPCR – G-protein-coupled receptors, HEK 293 – Human
Embryonic Kidney 293 cell line, pbFRET – photobleaching
FRET, Sst5 – somatostatin type 5 receptor, YFP – yellow fluo-
rescent protein
Introduction
Dopaminergic and somatostatinergic system interac-
tions have been suggested for many years based on
anatomical, behavioral and biochemical studies. It has
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been reported that dopamine administration regulates
somatostatin release in the rat striatum and hippocam-
pus [17] and that selective dopamine D1 and D2 re-
ceptor agonists increase somatostatin receptor density
in the striatum [8]. Likewise, somatostatin positively
modulates dopamine release in the striatum [3, 19].
Dopamine and somatostatin have also been impli-
cated in the pathophysiology of depression because of
their potential roles in mood regulation. Reduced lev-
els of somatostatin have been observed in the cerebro-
spinal fluid [10, 18] and recently in the subgenual an-
terior cingulate cortex [20] of depressive patients. In-
tracerebroventricular administration of somatostatin
results in an antidepressant-like effect in rats, as
shown by a forced swim test [6]. Furthermore,
chronic desipramine treatment selectively potentiates
somatostatin-induced dopamine release in the nucleus
accumbens and the striatum [12]. It has also been
shown that chronic administration of antidepressants
influences somatostatin levels and somatostatin re-
ceptor density in rat brains [13]. More recent studies
show that imipramine upregulates somatostatin release
in the mouse hypothalamus, eliciting antidepressant-
like effects in tail suspension test [11].
The molecular basis of this functional interaction
between the somatostatinergic and dopaminergic sys-
tems may stem from the interaction of the somatosta-
tin and dopamine receptors. These receptors were
found to share some similarities: they are members of
the G protein-coupled receptors (GPCRs) family, show
sequence homology and appear to be structurally re-
lated [6]. It has been demonstrated that members of
both superfamilies, when coexpressed in the same cell
and in the presence of specific ligands, may interact at
the membrane level, forming homo- and hetero-
dimers. These dimers may constitute a novel receptor
that can activate alternative pathways, possibly en-
hancingligand affinity and signal transduction [7].
It has been established by immunocytochemical
studies that the dopamine D2 and somatostatin Sst5
receptors colocalize in medium-sized aspiny interneu-
rons in the striatum and pyramidal neurons in the
cerebral cortex, an observation that suggests the pos-
sibility of functional interactions between these recep-
tors. It has been shown that the dopamine D2 and so-
matostatin Sst5 receptors, when coexpressed in the
same cell, undergo ligand-dependent heterodimeriza-
tion with enhanced functional activity. D2-Sst5 het-
erodimerization is associated with a modification in
ligand binding and a synergistic effect on the activa-
tion of the transduction pathway because both recep-
tors signal through the inhibition of adenylyl cyclase
via Gi proteins [16].
In the present study, we investigated the heterodi-
merization of the human D2 and Sst5 receptors upon
treatment with antidepressant drugs (desipramine and
citalopram) in the proposed in vitro model by employ-
ing biophysical approaches, such as photobleaching
fluorescence resonance energy transfer microscopy.
Förster (Fluorescence) Resonance Energy Transfer
(FRET) is a physical phenomenon that is being used
more and more in biomedical research and drug dis-
covery, as it allows the study of interactions between
proteins in a single cell. FRET is a process that relies
on the distance-dependent transfer of energy between
an excited donor molecule and an acceptor molecule
in a non-radiative way. This technique provides in-
sight into the interactions between proteins that are in
close proximity (less than 10 nm) to each other, which
makes it an excellent method for measuring the extent
to which receptors dimerize. One of the established
and commonly used techniques for measuring FRET
is acceptor photobleaching [14]. It is based on the fact
that FRET reduces the amount of fluorescence re-
leased by the donor fluorophore. This method in-
volves measuring the donor fluorescence intensity in
the same sample before and after destroying the ac-
ceptor by photobleaching. If FRET is initially present,
an increase in unquenched donor fluorescence occurs.
We used two antidepressant drugs with different
pharmacological profiles: desipramine a tricyclic an-
tidepressant that inhibits the continued uptake of
noradrenaline and, to a lesser extent, serotonin; and
citalopram, a serotonin uptake inhibitor. Although
none of the antidepressants used in this study have
any affinity for the dopaminergic or somatostatinergic
receptors [2], 48 h of incubation has been found to af-
fect their ability to form heterodimers.
Materials and Methods
Materials
HEK293 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). Cell culture
reagents were purchased from Gibco (Carlsbad, CA,
USA), Sigma-Aldrich (Poznañ, Poland) and PAA
Laboratories GmbH. Molecular biology reagents were
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obtained from Fermentas (Vilnius, Lithuania). Oligo-
nucleotides were synthesized by IBB PAN (Warszawa,
Poland). The pcDNA3.1(+) plasmids encoding human
Sst5 and D2 receptors were obtained from the UM-
RcDNA Resource Center (University of Missouri,
Rolla, MO, USA). The pECFP-N1 and pEYFP-N1
vectors were purchased from BD Biosciences, Clon-
tech (Palo Alto, CA, USA). Desipramine and citalo-
pram were obtained from Sigma-Aldrich (Poznañ,
Poland), and somatostatin-14 was obtained from Pro-
Spec(Rehovot, Israel).
Construction of fusion proteins
The human somatostatin Sst5 and D2 genes cloned
into the pcDNA3.1(+) plasmids were labeled with
cDNA encoding enhanced CFP (ECFP) or enhanced
YFP (EYFP). Briefly, the cDNAs encoding the D2
and Sst5 receptors were PCR-amplified. The primers
used were the forward universal primer for
pcDNA3.1(+) and the reverse primer, which removed
the STOP codon and introduced a unique Xho I re-
striction site. Using Nhe I and Xho I restriction en-
zymes, the entire coding sequences were inserted into
the pECFP-N1 and pEYFP-N1 vectors. Subsequently,
receptors tagged with CFP protein were used as the
fluorescence donor, and receptors tagged with YFP
were used as fluorescence acceptor.
Cell culture and transfection
Human Embryonic Kidney 293 (HEK 293) cells were
cultured on coverslips at 37°C and 5% CO2 atmos-
phere in Dulbecco’s modified essential medium sup-
plemented with 10% fetal bovine serum and 1% L-
glutamine. Using a calcium phosphate precipitation
procedure, the cells were transiently co-transfected
with the pcDNA3.1 plasmid containing the sequences
of the somatostatin Sst5 and dopamine D2 receptors
tagged with fluorescent proteins (CFP and YFP). At
48 h after transfection, the cells were incubated with
somatostatin-14 (1 µM) for 30 min or desipramine
and citalopram (10, 1 and 0.1 µM) for 24, 48 and 72 h,
and fixed with a 4% paraformaldehyde solution for
15 min at room temperature. Then, the cells were
washed, mounted onto slides and processed for confo-
cal microscopy FRET measurement.
Confocal microscopy – FRET measurement
Confocal laser scanning microscopy was performed
using a Leica TCS SP2 microscope (Leica Microsys-
tem, Mannheim, Germany). FRET was measured with
the Acceptor Photobleaching application using Leica
Software as follows: images in the CFP (donor) and
the YFP (acceptor) channel were acquired before pho-
tobleaching. A region of interest was selected, and the
acceptor (YFP) was photobleached by scanning re-
peatedly with the 514 nm laser line until the fluores-
cence signal was at the 50% level. Then, post-
photobleached images for CFP and YFP were
acquired by scanning with the appropriate laser line.
The FRET efficiency was calculated from the follow-
ing equation:
FRETeff = (Dpost – Dpre)/Dpost
where Dpost is the fluorescence intensity of the donor
after acceptor photobleaching, and Dpre is the fluores-
cence intensity of the donor before acceptor photo-
bleaching. The FRET efficiency is considered to be
positive when Dpost > Dpre.
Statistical analysis
The obtained data are presented as the mean ± SEM.
Statistical significance was evaluated using the t-test
or by a one-way ANOVA, followed by a Dunnett’s
test for post-hoc comparisons. For the statistical
analysis of the data, GraphPad Prism version 5.00 for
Windows (GraphPad Software) was used.
Results and Discussion
To investigate the interaction between the analyzed
receptors, we transiently co-transfected HEK 293
cells with dopamine D2 and somatostatin Sst5 recep-
tors tagged with fluorescent proteins (CFP, YFP).
Confocal microscopy observations indicated that both
dopamine D2 and somatostatin Sst5 receptors colo-
calize at the plasma membrane (Fig. 1).
First, the agonist-induced formation of hetero-
dimers was investigated. After 48 h of transfection,
cells were treated with somatostatin-14 (1 µM) for
30 min (according to [16]). The observed FRET effi-
ciency was markedly increased compared to the non-
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treated cells (9.74 ± 1.27% vs. 1.83 ± 0.59%, respec-
tively, p < 0.001) (Fig. 2). This result confirms previ-
ous reports that the heterodimerization of the somato-
statin Sst5 and dopamine D2 receptors is induced by
agonist stimulation and that in the absence of ligand,
nosignificant pre-formed heterodimers exist [6].
We then investigated the effect of antidepressant
drugs upon the dimerization of the Sst5 and D2 recep-
tors. The co-transfected cells were incubated for 24,
48 and 72 h with an antidepressant drug – either desi-
pramine or citalopram (Fig. 3).
Desipramine (at concentrations of 10, 1 and
0.1 µM) present in the incubation medium for 48 h in-
duced a significant increase in FRET efficiency
(respectively: 12.7 ± 2.7%, 15.1 ± 0.9%, 11.9 ± 1.7%
vs. 3.6 ± 1.2%, p < 0.05) in the cells coexpressing
both the Sst5 and D2 receptors. Similarly, citalopram
induced a significant increase in the FRET efficiency
that was measured following 48 h of citalopram being
present in the culture medium at concentrations of 10
and 1 µM (respectively: 12.4 ± 1.3% and 14.6 ± 1.8%
vs. 3.6 ± 1.2%, p < 0.01). No significant changes were
observed after 24 or 72 h of antidepressant presence
in the incubation medium.
The obtained data indicate that desipramine and
citalopram presence for 48 h in a culture medium af-
fects the ability of the Sst5 and D2 receptors to form
heterodimers, despite the lack of affinity of these
drugs for the dopamine or somatostatin receptors [2].
The present study provides the physical evidence,
based on FRET analysis, that antidepressants promote
dimerization of the Sst5 and D2 receptors. The
mechanism of this influence might be for antidepres-
sant drugs to modulate cell membrane fluidity, lead-
ing to the enhancement of receptor-receptor interac-
tions. Previous studies have shown that chronic anti-
depressant treatment can lead to alterations in the
lipid membrane, causing the redistribution of proteins
and allowing them to be more mobile and therefore
able to interact with each other [4]; however, this
antidepressant-induced increased mobility of mem-
brane proteins may also cause a disruption of their in-
teractions. On the other hand, in our preliminary stud-
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Fig. 1. Colocalization of fluorescently tagged somatostatin Sst5 and dopamine D2 receptors on the membrane surface of transiently trans-
fected HEK 293 cells. Sst5-CFP receptor is shown in green (A) and D2-YFP receptor is shown in red (B). Coexpression of Sst5 and D2 recep-
tors can be seen by the yellow color in the merged image (C)
Fig. 2. Somatostatin stimulation of HEK293 cells coexpressing sst5-
CFP (fluorescence donor) and D2-YFP (fluorescence acceptor)
receptors. Somatostatin-14 (1 µM) was present in the incubation
medium for 30 min. FRET efficiency was measured by acceptor
photobleaching. The data are presented as the mean ± SEM. The
statistical significance between the means was evaluated by the
t-test. (Asterisks indicate p < 0.001)
ies, we have observed an opposite effect of antidepres-
sants on a different pair of receptors, the dopamine
D1-D2 receptors, because a significant reduction in
FRET efficiency after 24 h of incubation with desi-
pramine (1 µM) was observed (Fig. 4). These findings
are in agreement with the recent studies of Pei et al.,
which show that the coupling between the dopamine
D1 and D2 receptors is markedly increased in the
postmortem brains of patients who had suffered from
major depression, and that uncoupling the D1–D2
receptor complex exerts an antidepressant-like effect
[15]. Therefore, the effect of antidepressant drugs on
D2-Sst5 receptor heterodimerization seems to be
specific.
In the present study, we validated the use of FRET
and photobleaching in the studies of membrane
protein dimerization in response to specific ligands
and drugs. The high sensitivity of pbFRET is ideally
suited for the study of molecular interactions in indi-
vidual cells. The acceptor photobleaching technique
has been widely used to demonstrate the oligomeriza-
tion of different pairs of receptors [1, 5, 16]. GPCR
oligomerization is difficult to analyze in native cells;
therefore, human embryonic kidney cell line 293, as
well as other cell lines, have been widely used in reso-
nance energy transfer studies of membrane receptors
because these cells provide an accepted model in
which fluorescently tagged receptor proteins can be
efficiently expressed [9]. Although the experiments
performed in transfected in vitro models do not repre-
sent a physiological state, it might be expected that
a similar situation occurs in the membranes of neural
cells coexpressing both receptors. However, such con-
clusionsneed to be confirmed in vivo.
Numerous biochemical and behavioral studies have
reported that dopamine and somatostatin may play
a role in the pathophysiology of depression. Somato-
statin is known to increase dopaminergic activity in
the striatum, although the specific receptors that me-
diate this effect are still unknown. The results pre-
sented in this work may be considered to be evidence
for a potential molecular mechanism underlying the
antidepressant-like effect of somatostatin, which in-
fluences dopamine-mediated behavioral responses.
Synergistic effects on the transduction pathway via di-
merization of the dopamine D2 and somatostatin Sst5
receptors may enhance the antidepressant effect. As
they are distinct from monomers, Sst5-D2 dimers
may also activate unknown signal pathways.
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Fig. 4. The effect of desipramine on changes in FRET efficiency in
HEK293 cells transiently cotransfected with plasmids containing
D1-YFP and D2-CFP fusion proteins. FRET efficiency was measured
by acceptor photobleaching. Cells were incubated with desipramine
(1 µM) for 24, 48 and 72 h prior to cell fixation. The data are presented
as the mean ± SEM. The statistical significance between the means
was evaluated by the t-test (* p < 0.05)
Fig. 3. FRET efficiency of the sst5-CFP and D2-YFP pairs by acceptor
photobleaching. The data are presented as the mean ± SEM. Antide-
pressant drugs (A  desipramine, B  citalopram) at concentrations
of 10, 1, or 0.1 µM, were present in the incubation medium for 24, 48
and 72 h prior to cell fixation. The statistical significance was evalu-
ated using a one-way ANOVA, followed by a Dunnetts test for post-
hoc comparisons. (* p < 0.05; ** p < 0.01; *** p < 0.001)
Dopamine D2 and somatostatin Sst5 heterodimers
with enhanced functional activity may be considered
to be novel mediators of antidepressant mechanisms
and may possibly serve as a new drug target in re-
search on the improvement of therapy for depression.
However, still more studies are required to elucidate
the physiological or pathological consequences of
heterodimerization invivo.
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